Enanta Pharmaceuticals, Inc. - Common Stock (NQ:ENTA)

11.79 +0.15 (+1.33%)

Delayed Quote Updated: 11:52 AM EDT, Oct 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Enanta Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Recap Of Friday's Biotech Catalysts - End of The Day Summary ↗

July 29, 2022

Via Benzinga

Enanta Shares Rise On Positive Data From Initial-Stage Covid-19 Study ↗

July 29, 2022

Enanta Pharmaceuticals (NASDAQ: ENTA) reported positive topline data from a Phase 1 study evaluating the safety, tolerability, and pharmacokinetics (PK) of orally administered single and multiple...

Via Benzinga

Daily Biotech Pulse: Bausch Health To Appeal Xifaxan Patent Decision, Bristol Myers Drug Combo Fails In Kidney Cancer Trial, Sarepta's Duchenne Candidate Update ↗

July 29, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Enanta's COVID-19 Treatment Shows Favorable Action In Healthy Participants ↗

July 29, 2022

Enanta Pharmaceuticals Inc (NASDAQ: ENTA) has announced topline data from a Phase 1 study of EDP-235 in healthy adult subjects. EDP-235, a coronavirus 3CL protease inhibitor, is designed to be a...

Via Benzinga

Analyst Ratings for Enanta Pharmaceuticals ↗

July 01, 2022

Within the last quarter, Enanta Pharmaceuticals (NASDAQ:ENTA) has observed the following analyst ratings:

Via Benzinga

Expert Ratings for Enanta Pharmaceuticals ↗

June 01, 2022

Enanta Pharmaceuticals (NASDAQ:ENTA) has observed the following analyst ratings within the last quarter:

Via Benzinga

Where Enanta Pharmaceuticals Stands With Analysts ↗

February 09, 2022

Enanta Pharmaceuticals (NASDAQ:ENTA) has observed the following analyst ratings within the last quarter:

Via Benzinga

Enanta Pharmaceuticals Announces Positive Data from a Phase 1 Clinical Study of EDP-235, its Oral 3CL Protease Inhibitor Designed for the Treatment of COVID-19

July 29, 2022

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Is Merck Stock A Buy Amid Reports It Could Buy Seagen For $40 Billion? ↗

July 07, 2022

Is Merck stock a buy as reports suggest it could put up $40 billion to acquire Seagen? Is MRK stock a buy right now?

Via Investor's Business Daily

This Analyst Says Arbutus' EASL Presentations Outline Path For A Functional Cure For Chronic Hepatitis B ↗

June 28, 2022

Via Benzinga

Enanta Pharmaceuticals Sues Pfizer Over Blockbuster Covid Pill Paxlovid ↗

June 22, 2022

Another company says it invented the technology behind the pill first.

Via Investor's Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For July 6, 2022 ↗

July 06, 2022

Upgrades

Via Benzinga

The Daily Biotech Pulse: Precision BioSciences Inks Gene Editing Pact, Athira Pharma's Alzheimer's Candidate Fails, Enanta Sues Pfizer Over COVID-19 Antiviral ↗

June 22, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Enanta Pharmaceuticals Files Patent Infringement Suit Against Pfizer

June 21, 2022

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals Announces Data Presentations at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2022

June 08, 2022

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals to Participate in Two Investor Conferences in June

June 02, 2022

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For June 1, 2022 ↗

June 01, 2022

Upgrades

Via Benzinga

The Daily Biotech Pulse: Valneva's COVID-19 Vaccine Filing Accepted By EMA, Enanta's RSV Candidate Fails, Orphan Drug Tag For Mersana's Gastric Cancer Candidate ↗

May 19, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Enanta Pharmaceuticals Shares Fall After RSVP Phase 2b study results Miss Primary Endpoint ↗

May 18, 2022

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) today announced the topline results for RSVP clinical study evaluating EDP-938, in otherwise healthy adults with community-acquired Respiratory Syncytial...

Via Benzinga

Enanta Pharmaceuticals Reports Topline Data from the RSVP Study of EDP-938 in Otherwise Healthy Adults with Community-Acquired Respiratory Syncytial Virus (RSV)

May 18, 2022

From Enanta Pharmaceuticals, Inc.

Via Business Wire

10 Biggest Price Target Changes For Tuesday ↗

May 10, 2022

Keybanc cut PubMatic, Inc. (NASDAQ: PUBM) price target from $48 to $27. PubMatic shares fell 1.5% to $18.71 in pre-market trading.

Via Benzinga

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2022 With Webcast and Conference Call Today at 4:30 p.m. ET

May 09, 2022

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals to Host Conference Call on May 9 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2022

May 02, 2022

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals Receives FDA Fast Track Designation for EDP-235, its Oral 3CL Protease Inhibitor Specifically Designed for the Treatment and Prevention of COVID-19

March 29, 2022

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals Announces Publication in The New England Journal of Medicine of Data from the Phase 2a Human Challenge Study of EDP-938 for the Treatment of Respiratory Syncytial Virus (RSV)

February 17, 2022

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharma Commences Dosing In Phase 1 COVID-19 Trial ↗

February 16, 2022

Enanta Pharmaceuticals Inc (NASDAQ: ENTA) has dosed the first subject in its Phase 1 trial of EDP-235, a coronavirus 3CL protease inhibitor, specifically designed as a...

Via Benzinga

Enanta Pharmaceuticals Doses First Subject in a Phase 1 Clinical Study of EDP-235, its Oral 3CL Protease Inhibitor Specifically Designed for the Treatment and Prevention of COVID-19

February 16, 2022

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Can Anyone Challenge Pfizer's Covid Dominance? Why These Biotechs Say Yes ↗

February 11, 2022

Drug behemoth Pfizer was the first to launch a Covid antiviral pill — but a pack of small biotech stocks are already nipping at its heels.

Via Investor's Business Daily

Enanta Pharmaceuticals to Present at the SVB Leerink 11th Annual Global Healthcare Conference

February 10, 2022

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals: Q1 Earnings Insights ↗

February 08, 2022

Enanta Pharmaceuticals (NASDAQ:ENTA) reported its Q1 earnings results on Tuesday, February 8, 2022 at 04:01 PM. Here's what investors need to know about the announcement.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.